D'Alessandro A, Federica G, Palini S, Bulletti C, Zolla L A mass spectrometry-based targeted metabolomics strategy of human blastocoele fluid: a promising tool in fertility research. Mol Biosyst. 2012 Apr;8(4):953-8. doi: 10.1039/c1mb05358b. Epub 2011 Oct 21.
Fanchin R, Ayoubi JM Uterine dynamics: impact on the human reproduction process. Reprod Biomed Online. 2009;18 Suppl 2:57-62. doi: 10.1016/s1472-6483(10)60450-6.
Hammadeh ME, Fischer-Hammadeh C, Ali KR Assisted hatching in assisted reproduction: a state of the art. J Assist Reprod Genet. 2011 Feb;28(2):119-28. doi: 10.1007/s10815-010-9495-3. Epub 2010 Nov 2.
Iwayama H, Hochi S, Yamashita M In vitro and in vivo viability of human blastocysts collapsed by laser pulse or osmotic shock prior to vitrification. J Assist Reprod Genet. 2011 Apr;28(4):355-61. doi: 10.1007/s10815-010-9522-4. Epub 2010 Dec 9.
Kato S, Janku F Cell-free DNA as a novel marker in cancer therapy. Biomark Med. 2015;9(7):703-12. doi: 10.2217/bmm.15.38.
Kawachiya S, Bodri D, Shimada N, Kato K, Takehara Y, Kato O Blastocyst culture is associated with an elevated incidence of monozygotic twinning after single embryo transfer. Fertil Steril. 2011 May;95(6):2140-2. doi: 10.1016/j.fertnstert.2010.12.018. Epub 2011 Jan 7.
Khalaf Y, El-Toukhy T, Coomarasamy A, Kamal A, Bolton V, Braude P Selective single blastocyst transfer reduces the multiple pregnancy rate and increases pregnancy rates: a pre- and postintervention study. BJOG. 2008 Feb;115(3):385-90. doi: 10.1111/j.1471-0528.2007.01584.x.
Magli MC, Gianaroli L, Ferraretti AP Chromosomal abnormalities in embryos. Mol Cell Endocrinol. 2001 Oct 22;183 Suppl 1:S29-34. doi: 10.1016/s0303-7207(01)00574-3.
MANDEL P, METAIS P [Nuclear Acids In Human Blood Plasma]. C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3. No abstract available. French.
Schwarzenbach H, Hoon DS, Pantel K Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426-37. doi: 10.1038/nrc3066. Epub 2011 May 12.
Sharma VK, Vouros P, Glick J Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids. Int J Mass Spectrom. 2011 Jul;304(2-3):172-183. doi: 10.1016/j.ijms.2010.10.003.
Son WY, Yoon SH, Yoon HJ, Lee SM, Lim JH Pregnancy outcome following transfer of human blastocysts vitrified on electron microscopy grids after induced collapse of the blastocoele. Hum Reprod. 2003 Jan;18(1):137-9. doi: 10.1093/humrep/deg029.
Stigliani S, Anserini P, Venturini PL, Scaruffi P Mitochondrial DNA content in embryo culture medium is significantly associated with human embryo fragmentation. Hum Reprod. 2013 Oct;28(10):2652-60. doi: 10.1093/humrep/det314. Epub 2013 Jul 25.
Stigliani S, Persico L, Lagazio C, Anserini P, Venturini PL, Scaruffi P Mitochondrial DNA in Day 3 embryo culture medium is a novel, non-invasive biomarker of blastocyst potential and implantation outcome. Mol Hum Reprod. 2014 Dec;20(12):1238-46. doi: 10.1093/molehr/gau086. Epub 2014 Sep 17.
Van Landuyt L, Polyzos NP, De Munck N, Blockeel C, Van de Velde H, Verheyen G A prospective randomized controlled trial investigating the effect of artificial shrinkage (collapse) on the implantation potential of vitrified blastocysts. Hum Reprod. 2015 Nov;30(11):2509-18. doi: 10.1093/humrep/dev218. Epub 2015 Sep 12.
Warton K, Samimi G Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci. 2015 Apr 22;2:13. doi: 10.3389/fmolb.2015.00013. eCollection 2015.
Wu CL, Li HG, Zhu CH [Advances in the studies of cell-free seminal DNA]. Zhonghua Nan Ke Xue. 2013 Jul;19(7):652-6. Chinese.
Artificial Shrinkage of Fresh Blastocyst: Impact on Success Rates in Assisted Reproductive Technology
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
